{"issuance_frequency":"","notes_translated":{"fr":"Le présent document d'orientation aidera toute personne qui collabore à la conduite d'essais cliniques de drogues sur des humains à comprendre le titre 5 de la partie C du Règlement sur les aliments et drogues (le Règlement) et à s'y conformer.","en":"This guidance document will help anyone who is involved in the conduct of clinical trials of drugs in humans to understand and comply with Part C, Division 5 of the Food and Drug Regulations (the Regulations)."},"issn":"","imso_approval":"true","isbn":"","creator":"","org_section":{"fr":"","en":""},"jurisdiction":"federal","private":false,"maintainer_email":"open-ouvert@tbs-sct.gc.ca","num_tags":0,"edition":"","frequency":"as_needed","data_series_issue_identification":{"fr":"","en":""},"contributor":{"fr":"","en":""},"maintainer":null,"ready_to_publish":"true","id":"eaa40f54-5cd3-4540-a644-e23e0fabb85d","metadata_created":"2021-05-04T18:10:55.507509","subject":["health_and_safety"],"pspc_identification_number":"","metadata_modified":"2021-05-04T18:10:55.507515","author":null,"author_email":null,"geographic_region":[],"portal_release_date":"2021-05-04","digital_object_identifier":"","state":"active","version":null,"keywords":{"fr":["Orientation","Partie C","Titre 5","Règlement sur les aliments et drogues","Médicaments pour essais cliniques","essais cliniques sur des sujets humains","GUI-0100"],"en":["Guidance","Part C","Division 5","Food and Drug Regulations","Drugs for Clinical Trials","Clinical Trials Involving Human Subjects","GUI-0100"]},"relationships_as_object":[],"creator_user_id":"2dc5a12f-2a6f-4822-8514-165ea6bb05d9","title_translated":{"fr":"Document d’orientation : Titre 5 de la partie C du Règlement sur les aliments et drogues « Drogues destinées aux essais cliniques sur des sujets humains » (GUI-0100)","en":"Guidance Document: Part C, Division 5 of the Food and Drug Regulations “Drugs for Clinical Trials Involving Human Subjects” (GUI-0100)"},"type":"info","resources":[{"cache_last_updated":null,"unique_identifier":"","package_id":"eaa40f54-5cd3-4540-a644-e23e0fabb85d","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"b261fd95-e2fc-4fba-bf71-f87e22a32cdf","related_relationship":"","name_translated":{"fr":"Document d’orientation : Titre 5 de la partie C du Règlement sur les aliments et drogues « Drogues destinées aux essais cliniques sur des sujets humains » (GUI-0100)","en":"Guidance Document: Part C, Division 5 of the Food and Drug Regulations “Drugs for Clinical Trials Involving Human Subjects” (GUI-0100)"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance Document: Part C, Division 5 of the Food and Drug Regulations “Drugs for Clinical Trials Involving Human Subjects” (GUI-0100)","language":["en"],"created":"2021-05-04T18:10:55.643230","url":"https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/good-clinical-practices/guidance-documents/guidance-drugs-clinical-trials-human-subjects-gui-0100/document.html","last_modified":null,"position":0,"revision_id":"c05efdd4-ae51-4b39-b6c7-26260231bc6a","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"eaa40f54-5cd3-4540-a644-e23e0fabb85d","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"ac53435a-de9e-49d8-a254-147e5efab0a1","related_relationship":"","name_translated":{"fr":"Document d’orientation : Titre 5 de la partie C du Règlement sur les aliments et drogues « Drogues destinées aux essais cliniques sur des sujets humains » (GUI-0100","en":"Guidance Document: Part C, Division 5 of the Food and Drug Regulations “Drugs for Clinical Trials Involving Human Subjects” (GUI-0100)"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance Document: Part C, Division 5 of the Food and Drug Regulations “Drugs for Clinical Trials Involving Human Subjects” (GUI-0100)","language":["fr"],"created":"2021-05-04T18:10:55.643236","url":"https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/conformite-application-loi/bonnes-pratiques-cliniques/documents-orientation/guide-drogues-destinees-essais-cliniques-sujets-humains-gui-0100/document.html","last_modified":null,"position":1,"revision_id":"c05efdd4-ae51-4b39-b6c7-26260231bc6a","resource_type":"publication"}],"place_of_publication":[],"num_resources":2,"tags":[],"spatial":"","collection":"publication","org_title_at_publication":{"fr":"Santé Canada","en":"Health Canada"},"date_published":"2019-08-20 00:00:00","issuance":"","groups":[],"license_id":"ca-ogl-lgo","data_series_name":{"fr":"","en":""},"relationships_as_subject":[],"license_title":"Open Government Licence - Canada","restrictions":"unrestricted","organization":{"description":"","created":"2016-09-23T17:25:33.001625","title":"Health Canada | Santé Canada","name":"hc-sc","is_organization":true,"state":"active","image_url":"","revision_id":"6a0471e8-36e5-4217-8f72-563c83e6465a","type":"organization","id":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","approval_status":"approved"},"name":"eaa40f54-5cd3-4540-a644-e23e0fabb85d","isopen":false,"additional_notes":{"fr":"","en":""},"departmental_identification_number":"","notes":"This guidance document will help anyone who is involved in the conduct of clinical trials of drugs in humans to understand and comply with Part C, Division 5 of the Food and Drug Regulations (the Regulations).","owner_org":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","program_page_url":{"fr":"","en":""},"url":null,"audience":[],"gc_catalogue_number":"","license_url":"http://open.canada.ca/en/open-government-licence-canada","series_publication_dates":{"fr":"","en":""},"title":"Guidance Document: Part C, Division 5 of the Food and Drug Regulations “Drugs for Clinical Trials Involving Human Subjects” (GUI-0100)","revision_id":"c05efdd4-ae51-4b39-b6c7-26260231bc6a"}